Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chi3l1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Chi3l1. Displaying page 1 of 1.
    EudraCT Number: 2016-004414-10 Sponsor Protocol Number: TERIFL08519 Start Date*: 2018-02-23
    Sponsor Name:MS Centrum, Department of Neurology, Sshlgrenska University Hospital
    Full Title: Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000647-30 Sponsor Protocol Number: EFC16645 Start Date*: 2020-08-27
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis
    Medical condition: Non-relapsing Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) FR (Completed) DE (Restarted) GB (GB - no longer in EU/EEA) CZ (Completed) NO (Completed) FI (Completed) DK (Completed) BE (Completed) LT (Completed) AT (Completed) GR (Completed) NL (Completed) PT (Completed) PL (Completed) HU (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000645-14 Sponsor Protocol Number: EFC16035 Start Date*: 2020-10-13
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
    Medical condition: Primary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BG (Trial now transitioned) EE (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) NO (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) LV (Completed) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000637-41 Sponsor Protocol Number: EFC16033 Start Date*: 2020-07-31
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) CZ (Completed) FI (Completed) SE (Completed) AT (Completed) DK (Completed) LT (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000644-55 Sponsor Protocol Number: EFC16034 Start Date*: 2020-12-22
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) LV (Completed) SK (Completed) BE (Completed) NO (Completed) GR (Completed) NL (Completed) PT (Completed) HU (Completed) HR (Completed) IT (Completed) EE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003195-13 Sponsor Protocol Number: 02/06/2021/2.0 Start Date*: 2021-06-23
    Sponsor Name:Fakultní nemocnice Ostrava
    Full Title: Importance of therapeutic monitoring of orally administered disease-modifying drugs used in the treatment of multiple sclerosis
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10064137 Progression of multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001862-13 Sponsor Protocol Number: AB19001 Start Date*: 2020-03-12
    Sponsor Name:ABScience
    Full Title: A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo ...
    Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FR (Trial now transitioned) BE (Prematurely Ended) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Ongoing) ES (Restarted) DK (Trial now transitioned) PL (Ongoing) IE (Prematurely Ended) IT (Prematurely Ended) NO (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:50:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA